Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;16(11):2598-2608.
doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Aaron M Goodman  1   2   3 , Shumei Kato  4   2 , Lyudmila Bazhenova  4 , Sandip P Patel  4 , Garrett M Frampton  5 , Vincent Miller  5 , Philip J Stephens  5 , Gregory A Daniels  4 , Razelle Kurzrock  4   2
Affiliations

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Aaron M Goodman et al. Mol Cancer Ther. 2017 Nov.

Abstract

Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non-small cell lung cancer (NSCLC). Our aim was to examine the relationship between TMB and outcome in diverse cancers treated with various immunotherapies. We reviewed data on 1,638 patients who had undergone comprehensive genomic profiling and had TMB assessment. Immunotherapy-treated patients (N = 151) were analyzed for response rate (RR), progression-free survival (PFS), and overall survival (OS). Higher TMB was independently associated with better outcome parameters (multivariable analysis). The RR for patients with high (≥20 mutations/mb) versus low to intermediate TMB was 22/38 (58%) versus 23/113 (20%; P = 0.0001); median PFS, 12.8 months vs. 3.3 months (P ≤ 0.0001); median OS, not reached versus 16.3 months (P = 0.0036). Results were similar when anti-PD-1/PD-L1 monotherapy was analyzed (N = 102 patients), with a linear correlation between higher TMB and favorable outcome parameters; the median TMB for responders versus nonresponders treated with anti-PD-1/PD-L1 monotherapy was 18.0 versus 5.0 mutations/mb (P < 0.0001). Interestingly, anti-CTLA4/anti-PD-1/PD-L1 combinations versus anti-PD-1/PD-L1 monotherapy was selected as a factor independent of TMB for predicting better RR (77% vs. 21%; P = 0.004) and PFS (P = 0.024). Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse tumors. Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB. Mol Cancer Ther; 16(11); 2598-608. ©2017 AACR.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Forest plots comparing TMB for patients treated with immunotherapy agents: responders vs. non-responders
The mean with standard deviation is represented. Panel A: Patients with all tumors excluding melanoma and NSCLC (N = 63) (P<0.0001). Panel B: Patients with all tumors including melanoma and NSCLC (N = 151) (P = 0.0001). Panel C: Patients with melanoma or NSCLC (N = 88) (P = 0.0003). Abbreviations: CR = complete response, mb = megabase, NSCLC = non small cell lung cancer; PD = progressive disease, PR = partial response, SD = stable disease, TMB = tumor mutational burden
Figure 2
Figure 2. Kaplan Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy)
Tick marks represent patients at the time of censoring, and P values were calculated using log-rank (Mantel-Cox) test. For a similar analysis by TMB low vs. intermediate to high, see Supplemental Figure 2. Panel A: PFS for patients with all tumor types excluding melanoma and NSCLC – TMB low to intermediate vs. high [P = 0.0033, HR = 0.35 (95% CI 0.19 to 0.64)]. For TMB low to intermediate, N = 40 with 35 events. For TMB high, N = 15 with 8 events. Panel B: PFS for patients with all tumor types including melanoma and NSCLC – TMB low to intermediate vs. high [P = 0.0005, HR = 0.36 (95% CI 0.23 to 0.58)]. For TMB low to intermediate, N = 80, with 66 events. For TMB high, N = 22 with 12 events. Panel C: PFS for patients with melanoma or NSCLC – TMB low to intermediate vs. high [P = 0.0402, HR = 0.36 (95% CI 0.17 to 0.77)]. For TMB low to intermediate, N = 40 with 31 events. For TMB high, N = 7 with 4 events. Panel D: OS for patients with all tumor types excluding melanoma and NSCLC – TMB low to intermediate vs. high for all tumor types excluding melanoma and NSCLC [P = 0.2836, HR = 0.59 (95% CI 0.25 to 1.40]. For TMB low to intermediate, N = 40 with 20 events. For TMB high, N = 15 with 5 events. Panel E: OS for patients with all tumor types including melanoma and NSCLC – TMB low to intermediate vs. high [P = 0.0557, HR = 0.44 (95% CI 0.23 to 0.87)]. For TMB low to intermediate, N = 80 with 36 events. For TMB high, N = 22 with 6 events. Panel F: OS for patients with melanoma or NSCLC – TMB low to intermediate vs. high [P = 0.0926, HR = 0.21 (95% CI 0.07 to 0.63)]. For TMB low to intermediate, N = 40 with 16 events. For TMB high, N = 7 with 1 events. Abbreviations: CI = confidence interval; HR = hazard ratio; NSCLC = non-small cell lung cancer; OS = overall survival; PD-1 = programmed death receptor-1; PD-L1 = programmed death receptor-ligand 1; PFS = progression free survival; TMB = tumor mutational burden
Figure 3
Figure 3. Linear correlation1 between TMB cutoff for OR2 for CR/PR rates and HR2 for PFS, and OS depending on TMB for patients treated with anti-PD-1/PD-L1 monotherapy (N = 102)
Panel A: OR for CR/PR rate depending on TMB cutoff (R2 = 0.1985, P = 0.0106, Y = 0.07617*X + 7.494). Panel B: HR for PFS depending on TMB cutoff (R2 = 0.1246, P = 0.0487, Y = −0.001184*X + 0.3886). Panel C: HR for OS depending on TMB cutoff (R2 = 0.1985, P = 0.0476, Y = −0.001275*X + 0.5462). 1Linear regression performed using the least squares method. 2Odds Ratio (OR) >1.0 implies higher chance of response. The OR was calculated by comparing RR above and below the cut-off for each value. Hazard Ratio (HR) <1.0 implies less chance of progression or death. The HR was evaluated by comparing OS above and below the cut-off for each value. Abbreviations: CR = complete response, HR = hazard ratio; mb = megabase, NSCLC = non small cell lung cancer; OR = odds ratio; OS = overall survival; PD-1 = programmed death receptor-1; PD-L1 programmed death receptor-ligand 1; PFS = progression free survival; PD = progressive disease; PR = partial response; SD = stable disease; TMB = tumor mutational burden
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30. - PubMed
    1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627–39. - PMC - PubMed
    1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28. - PubMed
    1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373:1803–13. - PMC - PubMed
    1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010;363:711–23. - PMC - PubMed

Publication types

MeSH terms